Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IdentiFy attRibutes Of uNcontrolled Severe asThma Patients trEateD With Tezepelumab: Italian Clinical Practice Study With the New bioloGic targEting TSLP

NCT06948396 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06948396
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06948396 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IdentiFy attRibutes Of uNcontrolled Severe asThma Patients trEateD With Tezepelumab: Italian Clinical Practice Study With the New bioloGic targEting TSLP
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Active, not recruiting
Start date
June 25, 2025
Completion date
May 30, 2027
Enrollment
315 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

asthma